Pluristem Therapeutics Inc. (PSTI)

4.14
NASDAQ : Health Technology
Prev Close 4.24
Day Low/High 4.14 / 4.30
52 Wk Low/High 3.24 / 13.50
Avg Volume 273.00K
Exchange NASDAQ
Shares Outstanding 15.55M
Market Cap 65.85M
EPS -2.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
4 Biotech Stocks Under $10 Moving Higher

4 Biotech Stocks Under $10 Moving Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

CORRECTING AND REPLACING -- Pluristem CEO To Participate In Key Roundtable Discussion At The 8th Annual New York Stem Cell Summit '13

CORRECTING AND REPLACING -- Pluristem CEO To Participate In Key Roundtable Discussion At The 8th Annual New York Stem Cell Summit '13

Industry Executives to Address Whether Stem Cell Therapies Can Turn the Traditional Pharma Model on Its Head

Pluristem CEO To Participate In Key Roundtable Discussion At The 8th Annual New York Stem Cell Summit '13

Pluristem CEO To Participate In Key Roundtable Discussion At The 8th Annual New York Stem Cell Summit '13

Industry Executives to Address Whether Stem Cell Therapies Can Turn the Traditional Pharma Model on Its Head

Pluristem Receives Approval To Expand Its Phase II Clinical Trial In Intermittent Claudication To Germany

Pluristem Receives Approval To Expand Its Phase II Clinical Trial In Intermittent Claudication To Germany

International Study Extends FDA Phase II Trial That Began in U.S.

Pluristem Initiates Final Validation Of New Manufacturing Facility

Pluristem Initiates Final Validation Of New Manufacturing Facility

Capacity Design of Over 150,000 PLX Doses Annually

The Rosen Law Firm Announces Investigation Of Securities Claims Against Pluristem Therapeutics, Inc. --- PSTI

The Rosen Law Firm Announces Investigation Of Securities Claims Against Pluristem Therapeutics, Inc. --- PSTI

The Rosen Law Firm announces that it is investigating potential securities claims against Pluristem Therapeutics, Inc.

Pluristem To Present At Oppenheimer 23rd Annual Healthcare Conference

Pluristem To Present At Oppenheimer 23rd Annual Healthcare Conference

PLX Cells for Hematology to be Focus of Session

Pluristem Issues Letter To Shareholders Highlighting Significant Achievements On Several Fronts

Pluristem Issues Letter To Shareholders Highlighting Significant Achievements On Several Fronts

Increasing Cash Position to About $70 Million, Targeting Future Clinical Trials in Bone Marrow Transplant Failure Indications, Progress in Clinical Trials, New Regulatory Approvals & New Manufacturing Facilities to Service Markets

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.

Pluristem Develops Point-of-Care Thawing Device For PLX Cells

Pluristem Develops Point-of-Care Thawing Device For PLX Cells

Positioned to Provide a Uniform PLX Cell Product With Every Dose

4 Biotech Stocks Under $5 Moving Higher

4 Biotech Stocks Under $5 Moving Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Third Critically Ill Patient Successfully Treated With Pluristem's PLX Cells Under Compassionate Use

Third Critically Ill Patient Successfully Treated With Pluristem's PLX Cells Under Compassionate Use

Patient With Blood Cancer, Acute Myeloid Leukemia, Experienced Improved Clinical Condition and Released From Hadassah Hospital

Pluristem Files For Orphan Drug Status With U.S. FDA For Use Of PLX Cells In Treatment Of Aplastic Anemia

Pluristem Files For Orphan Drug Status With U.S. FDA For Use Of PLX Cells In Treatment Of Aplastic Anemia

Pluristem to Establish Board of Key Opinion Leaders in Bone Marrow Transplants

Pluristem Commences U.S. FDA Phase II Clinical Trial For Intermittent Claudication

Pluristem Commences U.S. FDA Phase II Clinical Trial For Intermittent Claudication

Duke University Medical Center is 1st of 5 Sites Already Approved

Pluristem And World Renowned Charite Berlin-Brandenburg Center For Regenerative Therapies Renew Five-Year Collaborative Research Agreement

Pluristem And World Renowned Charite Berlin-Brandenburg Center For Regenerative Therapies Renew Five-Year Collaborative Research Agreement

Pluristem to Pursue New Therapies for Variety of Degenerative Disorders

Pluristem Receives Approval From Indian Ministry Of Health For Use Of PLX Cells In Phase II Trial For Treatment Of Buerger's Disease

Pluristem Receives Approval From Indian Ministry Of Health For Use Of PLX Cells In Phase II Trial For Treatment Of Buerger's Disease

Last Year U.S. FDA Designated Pluristem's PLX Cells Orphan Status for the Treatment of Buerger's Disease

Pluristem Moves Intermittent Claudication Indication Forward In Europe Through Collaboration With Cato Research

Pluristem Moves Intermittent Claudication Indication Forward In Europe Through Collaboration With Cato Research

14 Million People in the U.S. Suffer From Intermittent Claudication, a Subset of Peripheral Artery Disease, Costing $2.5 Billion Per Year

3 Biotech Stocks Under $10 Surging Higher

3 Biotech Stocks Under $10 Surging Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.

TheStreet Quant Rating: D- (Sell)